Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
The top July 4 fireworks, festivals, and food trucks in the Triangle + Maps
Recommended
5 On Your Side shares 7 simple ways to cut down your energy bill this summer
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
138.18
+0.69 (+0.50%)
Streaming Delayed Price
Updated: 11:56 AM EDT, Jul 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
144,807
Open
138.12
Bid (Size)
138.08 (4)
Ask (Size)
138.31 (1)
Prev. Close
137.49
Today's Range
137.36 - 139.03
52wk Range
93.28 - 148.37
Shares Outstanding
100,600,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
June 20, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals.
Via
Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Performance
YTD
+4.90%
+4.90%
1 Month
-1.24%
-1.24%
3 Month
+0.32%
+0.32%
6 Month
+4.90%
+4.90%
1 Year
+46.25%
+46.25%
More News
Read More
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
June 14, 2024
Via
Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Via
Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
June 13, 2024
Via
Chartmill
Key Takeaways From Neurocrine Biosciences Analyst Ratings
May 28, 2024
Via
Benzinga
Exploring NASDAQ:NBIX's quality characteristics.
May 27, 2024
Via
Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
May 24, 2024
Via
Chartmill
In the world of growth stocks, NASDAQ:NBIX shines as a value proposition.
May 23, 2024
Via
Chartmill
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
May 04, 2024
Via
Investor's Business Daily
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
May 03, 2024
Via
Investor's Business Daily
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
May 03, 2024
Via
Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
May 02, 2024
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
May 01, 2024
Via
Benzinga
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
May 02, 2024
Via
Chartmill
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
Via
Investor's Business Daily
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
Via
InvestorPlace
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
May 01, 2024
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
Via
Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
April 26, 2024
Via
Investor's Business Daily
3 Red-Hot Biotech Rockets Blasting Off in 2024
April 24, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
Via
Investor's Business Daily
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
April 16, 2024
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.